Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

(2012) T Saida et al.   Multiple Sclerosis Journal

Genetic and Infectious Profiles of Japanese Multiple Sclerosis Patients

(2012) Satoshi Yoshimura et al.   PLoS One

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

(2011) Bhupendra Khatri et al.   LANCET NEUROLOGY

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder

(2011) Ju-Hong Min et al.   Multiple Sclerosis Journal

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

(2010) Volker Brinkmann et al.   NATURE REVIEWS DRUG DISCOVERY

IFN -1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum

(2010) J. Shimizu et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

CombinedCYP2C9,VKORC1andCYP4F2frequencies among racial and ethnic groups

(2010) Stuart A Scott et al.   PHARMACOGENOMICS

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

(2009) G. Comi et al.   Multiple Sclerosis Journal